Frontiers in Immunology (Feb 2024)
Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy
- Jin Wang,
- Jin Wang,
- Jin Wang,
- Yu Cheng,
- Yu Cheng,
- Yu Cheng,
- Yulin Wang,
- Yulin Wang,
- Yulin Wang,
- Hengxin Liu,
- Hengxin Liu,
- Hengxin Liu,
- Shuang Wu,
- Shuang Wu,
- Shuang Wu,
- Guangwei Tian,
- Jinglei Qu,
- Jinglei Qu,
- Jinglei Qu,
- Xiujuan Qu,
- Xiujuan Qu,
- Xiujuan Qu
Affiliations
- Jin Wang
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Jin Wang
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Jin Wang
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Yu Cheng
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Yu Cheng
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Yu Cheng
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Yulin Wang
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Yulin Wang
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Yulin Wang
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Hengxin Liu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Hengxin Liu
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Hengxin Liu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Shuang Wu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Shuang Wu
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Shuang Wu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Guangwei Tian
- Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China
- Jinglei Qu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Jinglei Qu
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Jinglei Qu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Provincial Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- DOI
- https://doi.org/10.3389/fimmu.2024.1331506
- Journal volume & issue
-
Vol. 15
Abstract
Lymph node (LN) metastasis is a common mode of metastasis in advanced gastric cancer (GC), while axillary LN metastasis infrequently occurs in GC. There are few reports on this rare type of metastasis – especially its clinicopathological features – and systemic treatment are unclear. We describe a case of GC with extensive metastasis, including the rare axillary LN metastasis. The patient achieved partial response of optimal efficacy, who was treated with combination immunotherapy as second-line treatment for nearly two years. The potential mechanisms were revealed by clinical and immune characteristics, such as high expression of PD-L1, high tumor mutational burden (TMB-H), Epstein-Barr virus (EBV) positive and CD8+ tumor-infiltrating lymphocyte positive.
Keywords
